Maintaining Market Position: United Therapeutics’ Tyvaso DPI Amidst Competition and Future Growth Prospects

Analyst Roger Song from Jefferies maintained a Buy rating on United Therapeutics (UTHR – Research Report) and keeping the price target at $432.00.

Roger Song’s rating is based on the expectation of limited impact from the approval of a competing product, Yutrepia, which has a similar label to United Therapeutics’ Tyvaso DPI. Despite the competition, Tyvaso DPI’s established market presence and comparable pricing are expected to maintain its market share, especially given the low penetration of treprostinil in the target patient population.
Furthermore, the upcoming Phase 3 data for Tyvaso in idiopathic pulmonary fibrosis (IPF) is anticipated to be a significant value driver for United Therapeutics. This data could open a substantial multi-billion dollar market opportunity, reinforcing the Buy rating. The analyst also notes that Tyvaso DPI may have a favorable long-term benefit in patients switched from nebulized Tyvaso, which supports its competitive positioning.

UTHR’s price has also changed moderately for the past six months – from $378.130 to $314.840, which is a -16.74% drop .